Risk of recurrent major adverse limb events was lower in diabetes patients taking GLP-1 agents compared with DPP-4 inhibitors. Reduction of limb events was most significant for major amputations, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results